Bird flu - Potential Stock Winners Abcellera & Valneva
Posted: May 19, 2024
- Next potential pandemic is Bird flu - Abcellera (AI) has developed a vaccine with Eli Lilly, stock worth 15% of IPO - Valneva has approved vaccine against bird flu - Inactivated vaccines more in demand than MRNA vaccines - Pfizer acquired 9% stake in Valneva for a purchase price twice as high as what they paid
Stay ahead of the market with AI stock alerts & AI summaries of the latest earnings, stock ideas for free with Fluid Bot. Sign up now!